GYRE THERAPEUTICS, INC. (GYRE) Market Cap & Valuation Ratios
GYRE THERAPEUTICS, INC. (GYRE) has a market cap of $652.3M and a price-to-sales ratio of 5.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GYREGYRE THERAPEUTICS, INC.Follow GYRE — free
—
Price chart with a free account
- Market cap
- 652.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| GYRE | 0.7 | — | 5.0 | — | -0.9% | +17% | -14% | -28% |
| MLTX | 1.0 | — | — | — | — | — | — | -315% |
| SLN | 0.9 | — | — | — | -4.5% | -98% | — | — |
| NVCT | 0.7 | — | — | — | — | — | — | — |
| AKTX | 0.6 | — | — | — | -1.6% | — | — | -175% |
| PBYI | 0.6 | 21.2 | 2.1 | 11.6 | 7.2% | -3% | 13% | 27% |
| STTK | 0.6 | — | 487.7 | — | -7.5% | -67% | — | -72% |
| CBIO | 0.5 | — | 25.6 | — | — | — | — | — |
| DMAC | 0.5 | — | — | — | -6.7% | — | — | -139% |
| OVID | 0.4 | — | 192.4 | — | -13.0% | -76% | — | -52% |
| ASMB | 0.4 | — | 1.1 | — | -9.5% | +125% | -12% | -3% |
| Median of these 10 | 21.2 | 25.6 | 11.6 | -6.7% | -67% | 0.7% | -72% |
; EV/Sales 5.0 vs. 25.6.
Growth vs. price
each dot a company · hover or tap for valuesGYRE THERAPEUTICS, INC. — questions
- What is GYRE THERAPEUTICS, INC.'s market cap?
- $652.3M.
- What is GYRE THERAPEUTICS, INC.'s price-to-sales ratio?
- 5.5.
Every figure on this page comes from GYRE THERAPEUTICS, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.